Infants with Non-Syndromic Intrahepatic Biliary Atresia typically present with jaundice, which is a yellowing of the skin and eyes, within the first few weeks of life. Other symptoms may include dark urine, pale stools, and an enlarged liver or spleen. These symptoms arise because bile, which helps digest fats, cannot flow from the liver to the intestine, causing liver dysfunction.

The diagnostic workup for this condition involves a combination of clinical evaluation, laboratory tests, and imaging studies. Blood tests may show elevated liver enzymes and bilirubin levels. An abdominal ultrasound can assess liver structure and bile duct abnormalities. A liver biopsy, where a small tissue sample is examined under a microscope, can confirm the diagnosis by revealing characteristic changes in liver tissue.

The primary treatment for Non-Syndromic Intrahepatic Biliary Atresia is a surgical procedure called the Kasai portoenterostomy. This surgery aims to restore bile flow by connecting the liver to the small intestine. If the Kasai procedure is unsuccessful or if liver damage progresses, a liver transplant may be necessary. Supportive care, including nutritional support and medications to manage symptoms, is also important.

The prognosis for infants with Non-Syndromic Intrahepatic Biliary Atresia varies. Early surgical intervention can improve outcomes, but many children may still require a liver transplant later in life. Without treatment, the condition can lead to liver failure and other serious complications. Long-term follow-up with a pediatric hepatologist is essential to monitor liver function and overall health.

The exact cause of Non-Syndromic Intrahepatic Biliary Atresia is not well understood. It is believed to result from a combination of genetic and environmental factors. Some theories suggest that viral infections or immune system abnormalities during fetal development may play a role in its onset.

Non-Syndromic Intrahepatic Biliary Atresia is a rare condition, occurring in approximately 1 in 10,000 to 15,000 live births worldwide. It affects both males and females equally and is the most common cause of pediatric liver transplants. The incidence may vary slightly based on geographic and ethnic factors.

In Non-Syndromic Intrahepatic Biliary Atresia, the bile ducts inside the liver become inflamed and progressively destroyed. This blockage prevents bile from being excreted into the intestine, leading to its accumulation in the liver. The retained bile causes liver damage, fibrosis (scarring), and eventually cirrhosis, which is severe liver scarring that impairs liver function.

Currently, there are no known preventive measures for Non-Syndromic Intrahepatic Biliary Atresia due to its unclear etiology. Early detection and prompt treatment are the best strategies to manage the condition and prevent complications. Regular prenatal care and monitoring of newborns for early signs of jaundice can aid in timely diagnosis.

Non-Syndromic Intrahepatic Biliary Atresia is a serious liver condition in infants characterized by the absence or destruction of bile ducts within the liver. It leads to jaundice and other symptoms due to bile accumulation. Early surgical intervention is crucial for improving outcomes, though many children may still require a liver transplant. The condition's cause remains unclear, and it is a leading cause of pediatric liver transplants.

If your child is diagnosed with Non-Syndromic Intrahepatic Biliary Atresia, it is important to understand the condition and its implications. This liver disease affects bile flow, leading to jaundice and other symptoms. Treatment often involves surgery to restore bile flow, and in some cases, a liver transplant may be needed. Regular follow-up with healthcare providers is essential to manage the condition and ensure the best possible outcomes for your child.